Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.
Last trade$0.4241
Day change+$0.0591 (+16.19%)
Day range$0.372 – $0.457
Volume3,898,381
Market cap$45M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$46.06M
Price / earnings
—
Price / book
-1.23×
Price / sales
19.66×
EV / sales
-27.51×
EV / EBITDA
0.82×
Profitability
Earnings per share
-$0.67
Return on assets
-46.26%
Return on equity
224.44%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-1.58×
Current ratio
8.13×
Quick ratio
7.92×
Cash ratio
7.65×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$61.65M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for MIST, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$559K
$238K
$1.55M
$0
$0
$0
$0
$0
Cost of revenue
$32K
$14K
$0
$0
$0
$0
$0
$0
Gross profit
$527K
$224K
$1.55M
$0
$0
$0
$0
$0
Selling, general and administrative
$22.65M
$4.82M
$5.09M
$3.26M
$8.86M
$5.17M
$4M
$3.74M
Research and development
$3.51M
$3.25M
$5.52M
$3.94M
$3.67M
$4.98M
$3.94M
$3.96M
Total operating expenses
$26.16M
$23.89M
$18.8M
$11.83M
$12.53M
$20.52M
$12.35M
$9.62M
Operating income
-$25.63M
-$23.66M
-$17.26M
-$11.83M
-$12.53M
-$20.52M
-$12.35M
-$9.62M
Interest expense
-$4.73M
-$4.14M
-$985K
-$967K
-$951K
-$935K
-$919K
-$903K
Income before taxes
-$28.61M
-$26.07M
-$17.41M
-$11.92M
-$12.97M
-$20.76M
-$12.36M
-$9.44M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$28.61M
-$26.07M
-$17.41M
-$11.92M
-$12.97M
-$20.76M
-$12.36M
-$9.44M
Net income attributable to common shareholders
-$28.61M
-$26.07M
-$17.41M
-$11.92M
-$12.97M
-$20.76M
-$12.36M
-$9.44M
EBITDA
-$25.57M
-$23.61M
-$17.22M
-$11.8M
-$12.5M
-$20.5M
-$12.32M
-$9.59M
Basic earnings per share
-$0.21
-$0.20
-$0.16
-$0.12
-$0.20
-$0.31
-$0.19
-$0.14
Diluted earnings per share
-$0.21
-$0.20
-$0.16
-$0.12
-$0.20
-$0.31
-$0.19
-$0.14
Recent news
Company coverage with links to the original publishers.
Milestone Pharmaceuticals reported a Q3 loss of $0.18 per share, beating consensus estimates of $0.20 loss, with a 10% earnings surprise. The company posted $2.96 million in revenues, significantly surpassing estimates by 161.52%, compared to zero revenues a year ago. However, the stock has declined 67.6% year-to-date and carries a Zacks Rank #4 (Sell) rating due to unfavorable estimate revisions.
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) granted 33,000 stock options to a new employee as a hiring inducement. The options have an exercise price of $0.72 per share and vest over four years, with 25% vesting after one year followed by monthly installments. The grant was made under the company's 2021 Inducement Plan in compliance with Nasdaq regulations.
Milestone Pharmaceuticals Inc. granted 288,000 stock options to six new employees as a material inducement for hiring. The options have an exercise price of $1.32 per share and vest over four years, with 25% vesting after one year followed by monthly installments. The grants were made under the company's 2021 Inducement Plan in compliance with Nasdaq regulations.
Milestone Pharmaceuticals announced the RESET-PSVT registry, a Phase 4 observational study designed to generate real-world evidence on CARDAMYST (etripamil) nasal spray for treating paroxysmal supraventricular tachycardia (PSVT) in adults. The study, led by Duke Clinical Research Institute, will enroll approximately 450 patients across 20 sites beginning by end of 2026. CARDAMYST was FDA-approved in December 2025 and is now commercially available.
Milestone Pharmaceuticals received FDA approval for CARDAMYST, the first self-administered nasal spray for treating paroxysmal supraventricular tachycardia (PSVT) in adults, offering a novel at-home treatment option for over 2 million Americans with this heart condition.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.